DE60017888D1 - Dinatrium-salze, monohydrate und ethanol-solvate - Google Patents

Dinatrium-salze, monohydrate und ethanol-solvate

Info

Publication number
DE60017888D1
DE60017888D1 DE60017888T DE60017888T DE60017888D1 DE 60017888 D1 DE60017888 D1 DE 60017888D1 DE 60017888 T DE60017888 T DE 60017888T DE 60017888 T DE60017888 T DE 60017888T DE 60017888 D1 DE60017888 D1 DE 60017888D1
Authority
DE
Germany
Prior art keywords
ethanol solvate
delivery agents
disodium salt
ethanol
monohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60017888T
Other languages
English (en)
Other versions
DE60017888T2 (de
Inventor
E Bay
K Agarwal
Kiran Chaudhary
Shingai Majuru
M Goldberg
P Russo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emisphere Technologies Inc
Original Assignee
Emisphere Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Technologies Inc filed Critical Emisphere Technologies Inc
Application granted granted Critical
Publication of DE60017888D1 publication Critical patent/DE60017888D1/de
Publication of DE60017888T2 publication Critical patent/DE60017888T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/121,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/141,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/241,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26Two oxygen atoms, e.g. isatoic anhydride
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
DE60017888T 1999-04-05 2000-04-05 Dinatrium-salze, monohydrate und ethanol-solvate Expired - Lifetime DE60017888T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US12775499P 1999-04-05 1999-04-05
US127754P 1999-04-05
US18614200P 2000-03-01 2000-03-01
US18614300P 2000-03-01 2000-03-01
US186143P 2000-03-01
US186142P 2000-03-01
US19128600P 2000-03-21 2000-03-21
US191286P 2000-03-21
PCT/US2000/009390 WO2000059863A1 (en) 1999-04-05 2000-04-05 Disodium salts, monohydrates, and ethanol solvates

Publications (2)

Publication Number Publication Date
DE60017888D1 true DE60017888D1 (de) 2005-03-10
DE60017888T2 DE60017888T2 (de) 2006-01-19

Family

ID=27494697

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60017888T Expired - Lifetime DE60017888T2 (de) 1999-04-05 2000-04-05 Dinatrium-salze, monohydrate und ethanol-solvate

Country Status (12)

Country Link
US (6) US20020065255A1 (de)
EP (1) EP1175390B1 (de)
JP (2) JP4588221B2 (de)
AT (1) ATE288415T1 (de)
AU (1) AU4216700A (de)
CA (1) CA2369591C (de)
DE (1) DE60017888T2 (de)
ES (1) ES2235854T3 (de)
HK (1) HK1045680A1 (de)
IL (4) IL145546A0 (de)
NZ (1) NZ534409A (de)
WO (1) WO2000059863A1 (de)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461643B2 (en) 1993-04-22 2002-10-08 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
WO1997036480A1 (en) 1996-03-29 1997-10-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6440929B1 (en) 1998-07-27 2002-08-27 Emisphere Technologies, Inc. Pulmonary delivery of active agents
NZ509239A (en) 1998-07-27 2002-10-25 Emisphere Tech Inc 2-(4-(N-salicyloyl)aminophenyl)propionic acid useful as a carrier in compositions for delivering active agents
ES2235854T3 (es) * 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
US7151191B2 (en) * 2000-01-13 2006-12-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
EP1397156B1 (de) 2001-06-01 2007-03-14 Novartis AG Orale verabreichung von parathyroidhormon und calcitonin
WO2003015822A1 (en) * 2001-08-17 2003-02-27 Novartis Ag 5-cnac as oral delivery agent for parathyroid hormone fragments
JP5196701B2 (ja) * 2001-11-29 2013-05-15 エミスフィアー テクノロジーズ インコーポレイテッド クロモリンナトリウムの経口投与用製剤
EP2272501B1 (de) * 2002-01-09 2013-03-20 Emisphere Technologies, Inc. Polymorphe von Natrium 4-((4-chlor-2-hydroxybenzoyl) amino) butanoat
CA2473340C (en) 2002-02-20 2014-12-09 Eli Lilly And Company Formulations comprising a glp-1 compound and a delivery agent, and uses thereof
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) * 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
PE20040724A1 (es) * 2002-08-01 2004-12-06 Novartis Ag Composicion para la administracion oral de calcitonina
DE602004023093D1 (de) * 2003-07-11 2009-10-22 Novartis Ag N mit einem abgabemittel in mikronisierter form
PT2316473E (pt) 2003-07-23 2013-09-20 Novartis Ag Utilização de calcitonina na osteoartrite
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
DE602004004156T2 (de) 2003-08-20 2007-10-11 Eli Lilly And Co., Indianapolis Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4-rezeptor (mc4) als agonist wirkenden peptids
ATE361294T1 (de) 2003-08-20 2007-05-15 Lilly Co Eli Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagonartigen peptid (glp)-1-verbindung oder eines melanocortin-4- rezeptor-(mc4-)agonistschen peptids
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
CA2563335A1 (en) 2004-04-16 2005-12-08 Emisphere Technologies, Inc. 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
CN1953753B (zh) * 2004-05-06 2011-02-09 爱密斯菲尔科技公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
CN102040538B (zh) 2004-05-06 2013-02-13 爱密斯菲尔科技公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
RU2006138703A (ru) 2004-05-06 2008-06-20 Эмисфире Текнолоджис Твердая лекарственная форма увлажненного гепарина
KR101193228B1 (ko) * 2004-05-06 2012-10-22 에미스페어 테크놀로지스, 인코포레이티드 모노소듐 n-[8-(2-히드록시벤조일)아미노]카프릴레이트의 결정 다형 형태
CA2565188C (en) * 2004-05-14 2014-03-04 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
RU2530889C2 (ru) * 2004-05-14 2014-10-20 Эмисфире Текнолоджис, Инк. Соединения и составы для доставки активных веществ
NZ551241A (en) 2004-05-14 2010-08-27 Emisphere Tech Inc Aryl ketone compounds and compositions for delivering active agents
US9498487B2 (en) * 2004-05-19 2016-11-22 Emisphere Technologies, Inc. Topical cromolyn formulations
MXPA06013295A (es) * 2004-05-19 2007-02-22 Emisphere Tech Inc Formulaciones de aciclovir.
WO2006017251A2 (en) * 2004-07-12 2006-02-16 Emisphere Technologies, Inc. Compositions for delivering peptide yy and pyy agonists
JP2008509145A (ja) 2004-08-03 2008-03-27 エミスフィアー テクノロジーズ インコーポレイテッド 抗糖尿病性経口インスリン−ビグアニドの組み合わせ
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
GB0427600D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
GB0427603D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
EP1830831B1 (de) * 2004-12-29 2015-01-21 Emisphere Technologies, Inc. Pharmazeutische formulierungen von galliumsalzen
WO2006076692A1 (en) * 2005-01-12 2006-07-20 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
US8030271B2 (en) * 2005-07-05 2011-10-04 Emisphere Technologies, Inc. Compositions and methods for buccal delivery of human growth hormone
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
US8026392B2 (en) * 2005-09-19 2011-09-27 Emisphere Technologies, Inc. Crystalline forms of the di-sodium salt of N-(5-Chlorosalicyloyl)-8-aminocaprylic acid
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
EP1951207A2 (de) 2005-11-17 2008-08-06 Novartis AG Pharmazeutische zusammensetzung
US20070232537A1 (en) * 2005-12-19 2007-10-04 Nastech Pharmaceutical Company Inc. Intranasal pyy formulations with improved transmucosal pharmacokinetics
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
WO2007133944A2 (en) 2006-05-09 2007-11-22 Emisphere Technologies, Inc. Topical administration of acyclovir
EP2040718B1 (de) * 2006-06-28 2017-12-27 Emisphere Technologies, Inc. Galliumnitrid-formulierungen
CA2659655A1 (en) 2006-08-08 2008-02-21 Alan M. Fogelman Salicylanilides enhance oral delivery of therapeutic peptides
JP5577094B2 (ja) * 2006-08-31 2014-08-20 エミスフェアー・テクノロジーズ・インク 活性薬剤を送達するための化合物及び組成物
PL2059260T3 (pl) * 2006-08-31 2014-03-31 Novartis Ag Kompozycja farmaceutyczna obejmująca hGH do dostarczania doustnego
MX2009002121A (es) * 2006-09-07 2009-05-20 Hoffmann La Roche Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico.
CA2679782C (en) * 2007-03-02 2015-02-17 Novartis Ag Oral administration of a calcitonin
WO2008112706A1 (en) 2007-03-13 2008-09-18 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
PT2460515T (pt) 2007-08-09 2017-04-27 Novartis Ag Composições orais de calcitonina e suas aplicações
RU2469728C2 (ru) 2007-11-02 2012-12-20 Эмисфире Текнолоджис, Инк. Способ лечения дефицита витамина b12
JP5421368B2 (ja) * 2008-08-01 2014-02-19 パーデュー、ファーマ、リミテッド、パートナーシップ テトラヒドロピリジニルおよびジヒドロピロリル化合物およびそれらの使用
WO2010091199A2 (en) 2009-02-06 2010-08-12 The Regents Of The University Of California Calcium-binding agents induce hair growth and/or nail growth
AU2010223329B2 (en) * 2009-03-12 2016-07-21 Keybioscience Ag Treatment of diabetes and metabolic syndrome
EP2461803B1 (de) 2009-08-03 2018-10-17 Emisphere Technologies, Inc. Schnell wirkende naproxenzusammensetzung mit reduzierter wirkung auf magen und darm
EP2538945A4 (de) * 2010-02-24 2013-07-24 Emisphere Tech Inc Orale b12-therapie
AU2011264808B2 (en) * 2010-06-09 2015-01-22 Emisphere Technologies, Inc. Oral iron deficiency therapy
CA2808630A1 (en) 2010-08-19 2012-02-23 Buck Institute For Age Research Methods of treating mild cognitive impairment (mci) and related disorders
JP5978212B2 (ja) 2010-08-24 2016-08-24 アボット・ラボラトリーズAbbott Laboratories Hivコアタンパク質に特異的な抗体及びその使用
JP5913367B2 (ja) 2011-01-05 2016-04-27 ホスピーラ インコーポレイテッド バンコマイシンの噴霧乾燥
MX344925B (es) 2011-03-01 2017-01-11 N21 Acquisition Holding Llc Composiciones de insulina y cromo para el tratamiento y prevención de diabetes, hipoglucemia y alteraciones relacionadas.
ES2673617T3 (es) 2011-11-02 2018-06-25 Keybioscience Ag Miméticos de calcitonina para tratar enfermedades y trastornos
US9533022B2 (en) * 2011-11-02 2017-01-03 KeyBioscience A/S Peptide analogs for treating diseases and disorders
KR102019911B1 (ko) * 2011-11-02 2019-09-09 키바이오사이언스 아게 질병 및 장애 치료용 펩타이드 유사체
EP2884971A4 (de) 2012-08-16 2016-01-06 Ohio State Innovation Foundation Stat3-inhibitoren und ihre verwendung gegen krebs
EP2890370B1 (de) 2012-08-31 2019-10-09 The Regents of the University of California Mittel zur behandlung von adipositas, diabetes und verwandten erkrankungen
SG11201501850VA (en) 2012-09-21 2015-04-29 Intensity Therapeutics Inc Method of treating cancer
AU2013352141B2 (en) 2012-11-30 2018-04-05 The Regents Of The University Of California Anticonvulsant activity of steroids
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
CN105377873B (zh) 2013-07-12 2021-03-30 豪夫迈·罗氏有限公司 阐明离子交换层析输入优化
PT3068796T (pt) 2013-11-14 2018-03-02 Keybioscience Ag Miméticas de calcitonina para tratar doenças e distúrbios
EP3006045B3 (de) 2014-10-07 2021-03-17 Cyprumed GmbH Pharmazeutische Formulierungen zur oralen Verabreichung von Peptid- oder Proteinarzneimitteln
AU2015333689A1 (en) 2014-10-14 2017-05-25 The Regents Of The University Of California Use of CDK9 and BRD4 inhibitors to inhibit inflammation
GB201500263D0 (en) 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
CA2975578A1 (en) * 2015-02-09 2016-08-18 Entera Bio Ltd. Treatment of hypoparathyroidism
CN108135962A (zh) 2015-10-07 2018-06-08 塞浦路迈德有限责任公司 用于口服递送肽类药物的药物制剂
US11865121B2 (en) 2016-02-11 2024-01-09 Nutrition21, LLC Chromium containing compositions for improving health and fitness
BR112018071518A2 (pt) 2016-04-22 2019-02-19 Receptor Life Sciences, Inc. compostos medicinais à base de planta de ação rápida e suplementos nutricionais
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
CN110300595A (zh) 2017-01-05 2019-10-01 加利福尼亚大学董事会 Pac1受体激动剂(maxcap)及其用途
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
MX2020003330A (es) * 2017-10-05 2020-07-28 Receptor Holdings Inc Composiciones de hierbas con mejor biodisponibilidad.
MX2020003573A (es) * 2017-10-05 2020-08-03 Receptor Holdings Inc Formulaciones cannabinoides sinteticas y a base de plantas de inicio rapido y accion prolongada.
US11826414B2 (en) 2017-10-23 2023-11-28 Cz Biohub Sf, Llc Measurement of afucosylated IgG Fc glycans and related vaccination methods
WO2019193204A1 (en) 2018-04-06 2019-10-10 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
CN111057165A (zh) * 2020-01-13 2020-04-24 苏州健飞肠衣有限公司 一种高纯度肝素钠的制备方法
WO2022049310A1 (en) 2020-09-07 2022-03-10 Cyprumed Gmbh Improved pharmaceutical formulations of glp-1 receptor agonists
US11667614B2 (en) 2021-04-16 2023-06-06 Navinta III Inc. Process for the preparation of highly pure Salcaprozic Acid and pharmaceutically acceptable salts thereof
WO2022221629A1 (en) 2021-04-16 2022-10-20 Navinta Iii Inc Process for the preparation of highly pure salcaprozic acid and pharmaceutically acceptable salts thereof
KR20230173712A (ko) 2021-04-22 2023-12-27 씨비 바이오파마, 인크. 올리고뉴클레오티드의 경구 전달
AU2022311059A1 (en) 2021-07-16 2024-01-18 Novo Nordisk A/S Sodium n-(8-(2- hydroxybenzoyl)amino)caprylate polymorphic form a
WO2023166179A1 (en) 2022-03-03 2023-09-07 Cyprumed Gmbh Improved oral pharmaceutical formulations of therapeutic peptides and proteins

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES369853A1 (es) * 1969-07-24 1971-07-16 Bama S A Lab Procedimiento para la obtencion de derivados del acido ep- silon-amino-caproico.
US3795739A (en) * 1972-02-14 1974-03-05 Hoffmann La Roche Treatment of parkinson disease
US3939253A (en) * 1973-11-02 1976-02-17 Interx Research Corporation Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
US4061466A (en) * 1974-10-16 1977-12-06 Ingvar Gosta Holger Sjoholm Biologically active composition and the use thereof
DE2500157C2 (de) * 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
US4035507A (en) * 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
DE2517229A1 (de) * 1975-04-18 1976-10-28 Boehringer Mannheim Gmbh Phenylalkylcarbonsaeure-derivate und verfahren zu ihrer herstellung
DE2532420A1 (de) * 1975-07-19 1977-02-03 Boehringer Mannheim Gmbh Phenylessigsaeure-derivate und verfahren zu ihrer herstellung
CA1077842A (en) * 1975-10-09 1980-05-20 Minnesota Mining And Manufacturing Company Albumin medicament carrier system
FR2374910A1 (fr) * 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
NZ196349A (en) 1980-03-07 1984-08-24 Interx Research Corp Enhancement of absorption rate of orally administered polar bioactive agents
US4442090A (en) * 1980-11-09 1984-04-10 Kyoto Yakuhin Kogyo Kabushiki Kaisha Absorption-promoting compounds, compositions thereof with pharmaceuticals and/or bases for rectal administration and method of use
US4900730A (en) * 1981-01-14 1990-02-13 Toyo Jozo Co., Ltd. Preparation which promotes the absorption of peptides
GB2092136B (en) * 1981-01-17 1985-06-05 Mitsui Toatsu Chemicals Production of n-substituted amide compounds
CA1188987A (en) 1981-03-06 1985-06-18 Masataka Morishita Preparation having excellent absorption property
JPS58140026A (ja) * 1982-01-14 1983-08-19 Toyo Jozo Co Ltd 吸収性良好な製剤
IE54269B1 (en) * 1981-12-30 1989-08-02 Ici America Inc Pharmaceutically active phenylcarboxylic acid derivatives
US4654327A (en) * 1982-04-21 1987-03-31 Research Corp. Quaternary ammonium complexes of heparin
US4393192A (en) * 1982-12-21 1983-07-12 The Standard Oil Company Crystalline copolymers prepared from N,N'-terephthaloyldi-beta-alanine and a glycol
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
US4898729A (en) 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US4757066A (en) * 1984-10-15 1988-07-12 Sankyo Company Limited Composition containing a penem or carbapenem antibiotic and the use of the same
CA1234561A (en) 1985-06-26 1988-03-29 Kenneth M. White Profiled body roller-reamer stabilizer
IL77186A0 (en) 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
US4689182A (en) 1985-12-20 1987-08-25 Warner-Lambert Company Benzoic acid and benzoic acid ester derivatives having anti-inflammatory and analgesic activity
LU86258A1 (fr) * 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
USRE35862E (en) * 1986-08-18 1998-07-28 Emisphere Technologies, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
JPH0725725B2 (ja) * 1987-07-23 1995-03-22 保土谷化学工業株式会社 ベンズアミド誘導体
FR2636238B1 (fr) * 1988-09-14 1994-01-21 Morelle Jean Nouvelles compositions antisudorales
GB8823731D0 (en) 1988-10-10 1988-11-16 Smith Kline French Lab Biologically active compounds
FR2639395B1 (fr) 1988-11-18 1991-02-15 Rockwell Cim Dispositif d'accouplement entre une vitre et un mecanisme de leve-vitre a bras oscillants dans un vehicule automobile
JPH02239980A (ja) 1989-03-15 1990-09-21 Fuji Photo Film Co Ltd 感熱記録材料
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US6221367B1 (en) * 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US6099856A (en) * 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US5447728A (en) * 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5714167A (en) * 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5451410A (en) * 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
AU653026B2 (en) 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5811127A (en) * 1992-06-15 1998-09-22 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
HU211995B (en) * 1992-06-30 1996-01-29 Gyogyszerkutato Intezet Process to prepare novel benzoyl amino acid derivs. and pharmaceutical compns. contg.them
US5958457A (en) * 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
EP1025840B1 (de) * 1993-04-22 2005-06-29 Emisphere Technologies, Inc. Orale Dareichungsform
US5643957A (en) * 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5709861A (en) * 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
WO1997036480A1 (en) * 1996-03-29 1997-10-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6090958A (en) * 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) * 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5965121A (en) * 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CN1151836C (zh) * 1995-03-31 2004-06-02 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5989539A (en) * 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6051258A (en) 1995-06-07 2000-04-18 Emisphere Technologies, Inc. Proteinoid emulsions and methods for preparation and use thereof
US5750147A (en) * 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
GB2314189B (en) 1996-06-14 2000-08-09 Mars Inc Coin handling apparatus
US5876710A (en) * 1997-02-07 1999-03-02 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US5776888A (en) * 1997-02-07 1998-07-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5990166A (en) * 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6313088B1 (en) * 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US6051561A (en) * 1997-02-07 2000-04-18 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US5939381A (en) * 1997-02-07 1999-08-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6060513A (en) * 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5879681A (en) * 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5804688A (en) * 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ES2263428T3 (es) * 1997-02-07 2006-12-16 Emisphere Technologies, Inc. Compuesto y composicion para agentes activos de administracion.
US5863944A (en) * 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AR017426A1 (es) * 1997-12-08 2001-09-05 Smithkline Beecham Corp Sal de monoargininilo del acido (e)-3-[1-n-butil-5-[2-(2-carboxifenil)metoxi-4-clorofenil]-1h-pirazol-4-il]-2-[(5-metoxi-2,3-dihidrobenzofuran-6-il)metil]-prop-2-enoico, composicion farmaceutica que la contiene, su uso para la manufactura de un medicamento y procedimiento para su preparacion
NZ509239A (en) 1998-07-27 2002-10-25 Emisphere Tech Inc 2-(4-(N-salicyloyl)aminophenyl)propionic acid useful as a carrier in compositions for delivering active agents
BR9912975A (pt) 1998-08-07 2001-09-25 Emisphere Tech Inc Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
US6066015A (en) 1998-08-17 2000-05-23 Brown; James D. Method and system for anchoring a buoy via a screw-type anchor
AU3240900A (en) 1999-02-22 2000-09-04 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
ES2235854T3 (es) 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
US8158126B2 (en) 2005-08-25 2012-04-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Stem cell fusion model of carcinogenesis
US20070048725A1 (en) 2005-08-25 2007-03-01 Arrington Ben O'mar Machine perfusion of tissue grafts for transplantation
WO2011048589A2 (en) 2009-10-23 2011-04-28 Ben Gurion University Of The Negev Research And Development Authority Ion exchangers and methods of use thereof

Also Published As

Publication number Publication date
IL166158A0 (en) 2006-01-15
US8658695B2 (en) 2014-02-25
HK1045680A1 (en) 2002-12-06
US20100099621A1 (en) 2010-04-22
ATE288415T1 (de) 2005-02-15
US7659311B2 (en) 2010-02-09
US20020065255A1 (en) 2002-05-30
US8207227B2 (en) 2012-06-26
EP1175390A4 (de) 2002-09-04
EP1175390B1 (de) 2005-02-02
WO2000059863A1 (en) 2000-10-12
US20040106825A1 (en) 2004-06-03
JP2002541132A (ja) 2002-12-03
JP4588221B2 (ja) 2010-11-24
DE60017888T2 (de) 2006-01-19
JP2005068161A (ja) 2005-03-17
CA2369591C (en) 2011-06-14
ES2235854T3 (es) 2005-07-16
IL145546A (en) 2007-10-31
AU4216700A (en) 2000-10-23
US20110251125A1 (en) 2011-10-13
CA2369591A1 (en) 2000-10-12
IL166158A (en) 2010-12-30
US7384982B2 (en) 2008-06-10
JP4642435B2 (ja) 2011-03-02
US20120264834A1 (en) 2012-10-18
EP1175390A1 (de) 2002-01-30
IL145546A0 (en) 2002-06-30
NZ534409A (en) 2006-03-31
US20080269134A1 (en) 2008-10-30
US8003697B2 (en) 2011-08-23
IL180118A (en) 2010-12-30
IL180118A0 (en) 2007-06-03

Similar Documents

Publication Publication Date Title
DE60017888D1 (de) Dinatrium-salze, monohydrate und ethanol-solvate
BR0008405A (pt) Composição de fator viii formulada sem a adição de albumina, uso de uma composição de fator viii, e, método de liofilizar uma formulação farmacêutica aquosa
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
IL188230A0 (en) Stabilized liquid polypeptide-containing pharmaceutical compositions
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
HUP0300684A2 (hu) Szomatosztatin analógok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
RU2008123380A (ru) Фармацевтическая композиция
ATE311373T1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
HUP0401441A2 (hu) Az 5-CNAC mint mellékpajzsmirigy hormon fragmentumok orális hordozószere
RU2009136303A (ru) Пероральное введение кальцитонина
AR013157A1 (es) Composicion farmaceutica que incluye un analogo nucleotido y proceso para su preparacion
TW200744993A (en) Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid
RU2005105691A (ru) Пероральное введение кальцитонина
RS63804A (en) Stable salts of o-acetylsalicylic acid containing basic amino acids ii
IL128513A0 (en) Amino acid ester containing azole antifungals
JP2006524182A5 (de)
UY26365A1 (es) Sales de disodio, monohidratos, solvatos de etanol para la liberación de agentes activos
TH51556B (th) เกลือไดโซเดียม โมโนไฮเดรต และเอธานอลซอลเวต สำหรับการส่งมอบตัวกระทำที่ว่องไว
EA200500687A1 (ru) Применение дистронциевой соли 2-[n,n-ди(карбоксиметил)амино]-3-циано-4-карбоксиметилтиофен-5-карбоновой кислоты при получении лекарственных средств, предназначенных для лечения гастродуоденальной боли
AR036219A1 (es) Sales de disodio, monohidratos, solvatos de etanol para la liberacion de agentes activos
TH51556A (th) เกลือไดโซเดียม โมโนไฮเดรต และ เอธานอลซอลเวต สำหรับการส่งมอบตัวกระทำที่ว่องไว

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: EMISPHERE TECHNOLOGIES, INC., CEDAR KNOLLS, N., US